Protecting the Endothelium

FX CorDiax
At the heart of long-term haemodialysis
Protect your patient

 Innovative Helixone®plus membrane

Optimised membrane porosity for enhanced middle molecule removal

 Unique FX-class® design

Facilitates the best in cardioprotective haemodialysis therapy

 Outstanding endotoxin retention

Prevents the transfer of endotoxins into patients blood

 Unique INLINE steam sterilisation

No chemical residuals
The new FX CorDiax
Designed to Dialyse.
Built for Cardioprotection.
Innovative Helixone®plus membrane
Advances in fibre design allow better removal
of uremic toxin Inner
surface

The new membrane structure of Helixone®plus allows the

easy passage of middle molecules across the more porous
support region of the membrane.
Support
region
The fibre support region underneath the inner surface has
been opened up, optimising porosity and therefore the
convective filtration, flushing of larger uremic toxins such as
Close-up of the inner surface and the
β2-microglobulin ( ≈ 11,800 Da) or myoglobin
support region of the membrane.
( ≈ 17,000 Da).

At the same time the retention of beneficial molecules such

FX CorDiax 60 FX 60
as albumin is improved.
1.00 SCβ 0.90
2-m
The reduced transmembrane resistance improves the 0.90
0.80
Sieving Coefficient

SCβ 0.80
removal of a broad range of middle molecules as well as 0.70 2-m

low molecular weight substances. 0.60

SCMyo 0.50
0.50
0.40
0.30
SCMyo 0.28
0.20
0.10
1,000 10,000 100,000
Molecular Mass/Dalton

Comparison of sieving coefficient data of FX 60 and

FX CorDiax 60

1 0.014
0.9
0.012
0.8
Sieving Coefficient of Albumin

1)
0.7 0.010
3)
Sieving Coefficient

0.6
0.008
0.5
0.006
0.4

0.3 0.004
0.2
0.002
0.1
n.a. n.a. n.a. 2) 2)
0 0
i ax ta Hi TM H TM -H
iax ta H TM H TM -H
rDi iax ta Hi TM H TM -H
orD n
vo olyflu
x
lisi
o
Co evon lyflu
x io orD n
vo olyflu
x io
FX
C e E X Elis FX
C
Xe Elis
X P F X Po P

β2-microglobulin Myoglobin Albumin

(11,731 Da) (17,053 Da) (66,500 Da)

Comparison of sieving coefficients of FX CorDiax, Xevonta Hi, PolyfluxTM H, and ElisioTM-H.

(All data taken from manufacturer’s brochures. 1) > 0.8, 2) < 0.001, 3) < 0.01)
Unique FX-class® design
Optimised dialysate flow Homogenous blood Advanced
flow path Helixone®plus membrane
The 3-dimensional microwave structure, in combination with
the design of dialyser housing, ensures uniform dialysate
flow. This improves clearance values and the overall filter
performance.

Better haemodynamics
The refined blood inlet port improves haemodynamics and
the new design eliminates the risk of bloodline kinking.

Environmentally friendly
3-dimensional wave structure
The FX-class® dialysers weigh less than 50% of previous of the fibre

dialysers and use ecologically friendly materials.

Radial dialysate flow

Outstanding endotoxin retention

Greater protection through active prevention
Membranes such as Helixone®, which have a high
endotoxin retention capacity1, protect the patient from
inflammation, particularly when ultrapure dialysate is not
available.

Amyloidosis, immune disorders, or accelerated

atherosclerosis can be the result of using a membrane
with a low endotoxin retention capacity, and inflammation
can lead to an increased need for EPO.

Unique INLINE steam sterilisation

Clean and safe
FX-class® dialysers are sterilised using the unique INLINE
steam sterilisation process specifically developed by
Fresenius Medical Care.

This protects your patient from cytotoxic and carcinogenic

residuals2 caused by degraded and altered material inside
the dialyser produced during gamma sterilisation.

A further effect of this clean and safe process is the reduced
activation of the complement system3 and the low rinsing
volume helps reduce costs and preparation time.
Reference
1. Weber V. et al., Blood Purif (2003); 21: 365.
2. Shintani H. et al., Journal of Analytical Toxicology (1989); 13: 354-357.
3. Müller T. F. et al., Nephron (1998); 78: 139-142.
Improved Survival – Better Outcomes Albumin
β2-microglobulin

The use of High-Flux membranes such as FX-class® High-Flux

dialysers improves patient survival rates.

Enhanced middle molecule removal contributes to a reduction

of the complications of haemodialysis as well as improving
long-term patient outcomes.1

The results of the MPO study indicate the beneficial effect of High-Flux membranes in terms of reduced mortality for patients with serum
albumin levels ≤ 4.0 g/dL or diabetes.2

Patients with Serum Albumin ≤ 4 g/dL (p = 0.032)

High-Flux Membrane Low-Flux Membrane
1.00

0.90

0.80
Survival Probability of Patients

0.70

0.60

0.50

0.40

0.30

0.20
0 12 24 36 48 60 72 84
Months

Kaplan-Meier survival curves for the population of patients with serum albumin levels <_ 4.0 g/dL (log-rank test p = 0.032).2
(Graph adapted from original publication)

 Improved patient survival 2

 Reduced inflammation 3
 Better anemia control with reduced EPO doses 4
 Immune dysfunctions may be reversed 5

Reference
1. Tattersall J. et al., Nephrol Dial (2007); 22(Suppl.2); ii5-ii21. 4. Bonforte G.et al., Blood Purif (2002); 20: 357-363.
2. Locatelli F. et al., Journal of American Society of Nephrology (2009); 20: 645-654. 5. Lonnemann G. et al., Blood Purif (2003); 21(3): 225-231.
3. Pedrini L. A. et al., Nephrol Dial Transplant (2011); 26(8): 2617-2624.
The new FX CorDiax

Performance Data
Sieving coefficients of FX CorDiax Molecular weight
High-Flux Dialysers and Haemodia filters (Dalton)
Albumin 66,500 < 0.001
Myoglobin 17,053 0.5
β2-microglobulin 11,731 0.9
Inulin 5,200 1
Membrane material Helixone®plus
Sterilisation method INLINE steam
Housing material Polypropylene
Potting compound Polyurethane
Units per box 24

FX CorDiax High-Flux Dialysers FX CorDiax 40 FX CorDiax 50 FX CorDiax 60 FX CorDiax 80 FX CorDiax 100 FX CorDiax 120
Clearance (QB = mL/min) 200 200 300 300 300 300
Cytochrome c 12,230 48 71 96 111 125 136
Inulin 5,200 56 81 116 127 144 149
Vitamin B12 1,355 96 126 175 190 207 213
Phosphate 132 142 173 237 248 258 262
Creatinine 113 155 180 252 261 272 274
Urea 60 175 191 271 280 283 284
Clearance (QB = mL/min) 300 400 400 400 400
Cytochrome c 12,230 76 100 117 133 145
Inulin 5,200 88 122 135 154 160
Vitamin B12 1,355 144 191 209 229 237
Phosphate 132 215 270 285 299 305
Creatinine 113 229 290 303 321 325
Urea 60 255 319 336 341 343
In vitro performance: QD = 500 mL/min, QF = 0 mL/min, T = 37°C (EN 1283, ISO 8637). Ultrafiltration coefficients: human blood, Hct 32 %, protein content 6%.
Ultrafiltration coeff. (mL/h x mmHg) 21 33 47 64 74 87
Effective surface (m²) 0.6 1.0 1.4 1.8 2.2 2.5
K O A Urea 547 886 1,164 1,429 1,545 1,584
Priming volume (mL) 32 53 74 95 116 132
Article number F00005649 F00005650 F00005651 F00005652 F00005653 F00005654

FX CorDiax Haemodiafilters FX CorDiax 600 FX CorDiax 800 FX CorDiax 1000

Clearance (QB = 300 mL/min, QF = 75 mL/min)
Cytochrome c 12,230 131 141 151
Inulin 5,200 144 156 166
Vitamin B12 1,355 204 217 225
Phosphate 132 257 267 271
Creatinine 113 271 277 280
Urea 60 285 291 292
Clearance (QB = 400 mL/min, QF = 100 mL/min)
Cytochrome c 12,230 149 160 172
Inulin 5,200 166 178 190
Vitamin B12 1,355 235 251 262
Phosphate 132 307 321 328
Creatinine 113 327 339 343
Urea 60 354 365 367
In vitro performance: QD = 500 mL/min, T = 37°C (EN 1283, ISO 8637). Ultrafiltration coefficients: human blood, Hct 32 %, protein content 6%.
Ultrafiltration coeff. (mL/h x mmHg) 46 62 76
Effective surface (m²) 1.6 2.0 2.3
K O A Urea 1,148 1,365 1,421
Priming volume (mL) 95 115 136
Article number F00005655 F00005656 F00005657
 AP367/HD/AU/2014 © copyright 2013 Fresenius Medical Care Asia Pacific Limited

Fresenius Medical Care Australia Pty Ltd. · Level 17, 61 Lavender Street, Milsons Point, NSW 2061, Sydney, Australia
Telephone: (61 2) 9466 8000 · Fax: (61 2) 9929 5595 · www.fmc-ag.com